Compare American Financial Group Inc (AFG) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Financial Group Inc vs Mesoblast Limited — how do they compare? American Financial Group Inc trades at $144.65 (market cap $11.97B), while Mesoblast Limited trades at $16.96 (market cap $2.21B). The key difference: American Financial Group Inc is far larger — about 5.4× Mesoblast Limited's market cap, and American Financial Group Inc pays a 2.44% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| AFG | MESO | |
|---|---|---|
Market Cap | $11.97B | $2.21B |
Sector | Financials | Technology |
52-Week High | $148.71 | $20.96 |
52-Week Low | $124.18 | $12.88 |
Enterprise Value | $12.35B | $2.21B |
Dividend Yield | 2.44% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
